Catherine Pickering, iOnctura CEO

iOnc­tura rais­es €80M to ad­vance ear­ly-stage rare eye can­cer treat­ment

iOnc­tura has col­lect­ed €80 mil­lion ($85.9 mil­lion) in a Se­ries B round to sup­port its lead can­cer can­di­date through a Phase 2 test in uveal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.